RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Tanvex BioPharma - Stock

Tanvex BioPharma Liabilities 2024

Tanvex BioPharma Liabilities

1.94 B TWD

Ticker

6541.TW

ISIN

KYG8676P1037

In 2024, Tanvex BioPharma's total liabilities amounted to 1.94 B TWD, a -4.24% difference from the 2.03 B TWD total liabilities in the previous year.

Tanvex BioPharma Aktienanalyse

What does Tanvex BioPharma do?

Tanvex BioPharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Tanvex BioPharma's Liabilities

Tanvex BioPharma's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Tanvex BioPharma's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Tanvex BioPharma's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Tanvex BioPharma's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Tanvex BioPharma’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Tanvex BioPharma Stock

What is the level of liabilities of Tanvex BioPharma this year?

Tanvex BioPharma has a debt balance of 1.94 B TWD this year.

What were the liabilities of Tanvex BioPharma compared to the previous year?

The liabilities of Tanvex BioPharma have increased by -4.24% dropped compared to the previous year.

What are the consequences of high debt for investors of Tanvex BioPharma?

High liabilities can pose a risk for investors of Tanvex BioPharma, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Tanvex BioPharma?

Low liabilities mean that Tanvex BioPharma has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Tanvex BioPharma affect the company?

An increase in liabilities of Tanvex BioPharma can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Tanvex BioPharma affect the company?

A decrease in the liabilities of Tanvex BioPharma can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Tanvex BioPharma?

Some factors that can influence the liabilities of Tanvex BioPharma include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Tanvex BioPharma so important for investors?

The liabilities of Tanvex BioPharma are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Tanvex BioPharma take to modify the liabilities?

To change its liabilities, Tanvex BioPharma can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Tanvex BioPharma pay?

Over the past 12 months, Tanvex BioPharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Tanvex BioPharma is expected to pay a dividend of 0 TWD.

What is the dividend yield of Tanvex BioPharma?

The current dividend yield of Tanvex BioPharma is .

When does Tanvex BioPharma pay dividends?

Tanvex BioPharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Tanvex BioPharma?

Tanvex BioPharma paid dividends every year for the past 0 years.

What is the dividend of Tanvex BioPharma?

For the upcoming 12 months, dividends amounting to 0 TWD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Tanvex BioPharma located?

Tanvex BioPharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Tanvex BioPharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Tanvex BioPharma from 6/25/2024 amounting to 0 TWD, you needed to have the stock in your portfolio before the ex-date on 6/25/2024.

When did Tanvex BioPharma pay the last dividend?

The last dividend was paid out on 6/25/2024.

What was the dividend of Tanvex BioPharma in the year 2023?

In the year 2023, Tanvex BioPharma distributed 0 TWD as dividends.

In which currency does Tanvex BioPharma pay out the dividend?

The dividends of Tanvex BioPharma are distributed in TWD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Tanvex BioPharma

Our stock analysis for Tanvex BioPharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Tanvex BioPharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.